<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04689178</url>
  </required_header>
  <id_info>
    <org_study_id>RC20_0364</org_study_id>
    <nct_id>NCT04689178</nct_id>
  </id_info>
  <brief_title>IMproving Patient Adherence to Cervical Cancer Screening: a Randomized Trial Based on Reporting Women Who Did Not Perform a PAP Test Over the Last 3 Years to GP (IMPACT GP)</brief_title>
  <acronym>IMPACT GP</acronym>
  <official_title>IMproving Patient Adherence to Cervical Cancer Screening: a Randomized Trial Based on Reporting Women Who Did Not Perform a PAP Test Over the Last 3 Years to GP (IMPACT GP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Context:&#xD;
&#xD;
      In France, cervical cancer (CC) screening was opportunistic until recently. The target&#xD;
      population includes women aged 25 to 65 years. About 66% of women aged 25-40 years have&#xD;
      performed a screening test over the last three years but this figure decreases to 55% in&#xD;
      women over 40. The third &quot;Cancer Plan&quot; proposed by the French National Institute for Cancer&#xD;
      recommends to achieve an 80% participation in eligible women.&#xD;
&#xD;
      Improving women compliance to CC screening is a major challenge to decrease cancer incidence&#xD;
      and mortality.&#xD;
&#xD;
      To improve patient adherence, a CC screening organization will be launched in 2020 at a&#xD;
      national scale in France. Women who did not perform a PAP test over the last 3 years will&#xD;
      receive an invitation letter from the local public health association in charge of cancer&#xD;
      screening organization. The invitation letter will remind women that they should consult a&#xD;
      healthcare professional (a general practitioner (GP), a gynecologist or a midwife) to perform&#xD;
      a screening test.&#xD;
&#xD;
      Providing GPs with a list of their non-adherent patients could also improve women compliance&#xD;
      to CC screening recommendations.&#xD;
&#xD;
      The study objective is to assess whether sending both an invitation letter to non-adherent&#xD;
      women and a list of their non-adherent patients to GPs (&quot;invitation letter + GP reminder&quot;&#xD;
      group) could increase the proportion of women who perform a screening test, compared to only&#xD;
      sending an invitation letter to non-adherent women (&quot;invitation letter&quot; group) or not sending&#xD;
      any invitation (&quot;usual care&quot; group).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design, Setting and Participants:&#xD;
&#xD;
      The investigators will conduct a 3-arm, cluster-randomized, controlled trial in the&#xD;
      Loire-Atlantique region, in France.&#xD;
&#xD;
      The study will include a total of 1,500 GPs and about 100,000 women. The randomization will&#xD;
      be based on GP practices to avoid a contamination bias resulting from shared tracking&#xD;
      mechanisms and communication between GPs within a given practice. Thus, several GPs working&#xD;
      in the same practice will be assigned to the same study arm. Women on the patient list of a&#xD;
      given GP will be assigned to the arm of this GP.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      After a cluster randomization according to the practice, the GPs and their female patients&#xD;
      will be included in one of the following 3 arms:&#xD;
&#xD;
        -  &quot;Invitation letter + GP reminder&quot; (Arm 1): 40-65 year-old women who did not perform a&#xD;
           PAP test over the last 3 years will receive an invitation to consult a health&#xD;
           professional to perform a screening test, AND GPs will receive the list of their 40-65&#xD;
           year-old patients who did not perform a PAP test over the last 3 years;&#xD;
&#xD;
        -  &quot;Invitation letter&quot; (Arm 2): 40-65 year-old women who did not perform a PAP test over&#xD;
           the last 3 years will receive an invitation to consult a health professional to perform&#xD;
           a screening test. GPs will NOT receive any list of their non-adherent patients.&#xD;
&#xD;
        -  &quot;Usual care&quot; (arm 3): 40-65 year-old women who did not perform a PAP test over the last&#xD;
           3 years will NOT receive any invitation to consult a health professional to perform a&#xD;
           screening test. GPs will NOT receive any list of their non-adherent patients.&#xD;
&#xD;
      Expected Results&#xD;
&#xD;
      The investigators expect an increase in the proportion of women who perform a screening test&#xD;
      in the intervention arm (arm 1), compared to arms 2 and 3. Previous studies have suggested&#xD;
      that the proportion of women adherent to CC screening could be increased by 25% in arm 1&#xD;
      compared to arm 3, whereas the participation could be increased by 15% in arm 2 compared to&#xD;
      arm 3.&#xD;
&#xD;
      Considering that the proportion of adherent women in arm 3 should be of about 55%, the&#xD;
      absolute increase in participation could reach 11% in arm 1, and 6.6% in arm 2.&#xD;
&#xD;
      A higher adherence to CC screening could improve the detection of pathological lesions by 5%&#xD;
      for pathological pap smears and by 10% for positive HPV tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2, 2021</start_date>
  <completion_date type="Anticipated">July 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the proportion of women aged 40-65 who performed a screening test (HPV test or PAP smear) over the last 3 years, 6 months after the intervention</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of the test results: rate of PAP smears performed on the totality of tests : percentage of PAP smears</measure>
    <time_frame>20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of the test results: rate of HPV tests performed on the totality of tests : percentage of HPV tests</measure>
    <time_frame>20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of the test results: rate of abnormal tests (PAP smears, HPV tests, biopsies, cervical conizations) : percentage of abnormal tests.</measure>
    <time_frame>20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the test results</measure>
    <time_frame>20 months</time_frame>
    <description>To describe the results after a &quot;reflex test&quot; (Pap smear after a positive HPV test): percentage of high-grade lesions identified, second- and third-grade cervical intra-epithelial neoplasia, including in situ carcinoma, and cancers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the Factors Associated with a Lower Participation in Screening</measure>
    <time_frame>20 months</time_frame>
    <description>Several factors are associated with the non-adherence to CC screening. Our study will analyze the impact of our intervention on the participation rate, especially in the following populations: in patients over 50, and in patients with low income.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the healthcare pathways for women performing a CC screening test</measure>
    <time_frame>20 months</time_frame>
    <description>We will assess the proportion of each category of healthcare professional that women turn to for performing a screening test : GPs, midwives and gynecologists</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the healthcare pathways for women performing a CC screening test: describe the timeframe in which women performed the screening test after receiving the invitation</measure>
    <time_frame>20 months</time_frame>
    <description>Time between the receipt of the invitation and the date of the screening test, in months .</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">95000</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Invitation letter + GP reminder (Arm 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Invitation letter (Arm 2)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care (Arm 3)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Invitation letter + GP reminder</intervention_name>
    <description>40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test, AND GPs will receive the list of their 40-65 year-old patients who did not perform a PAP test over the last 3 years</description>
    <arm_group_label>Invitation letter + GP reminder (Arm 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Invitation letter</intervention_name>
    <description>40-65 year-old women who did not perform a PAP test over the last 3 years will receive an invitation to consult a health professional to perform a screening test. GPs will NOT receive any list of their non-adherent patients.</description>
    <arm_group_label>Invitation letter (Arm 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for GPs:&#xD;
&#xD;
        - All GPs practicing in the Loire-Atlantique region (Western France) will be included.&#xD;
&#xD;
        Inclusion criteria for patients :&#xD;
&#xD;
          -  women aged 40 to 65 years,&#xD;
&#xD;
          -  being on the patient list of the GPs participating in the study,&#xD;
&#xD;
          -  living in the Loire-Atlantique region (Western France),&#xD;
&#xD;
          -  being affiliated to the National Health Insurance.&#xD;
&#xD;
        Exclusion Criteria for GPs:&#xD;
&#xD;
        - GPs who could refuse to participate by contacting the research team.&#xD;
&#xD;
        Inclusion criteria for patients :&#xD;
&#xD;
          -  Refusal to participate to the study&#xD;
&#xD;
          -  Female patients who underwent total hysterectomy and those who received a pathological&#xD;
             result of a previous pap smear (asc-us or CIN) are not eligible to participate in the&#xD;
             CC screening and therefore excluded from the study.&#xD;
&#xD;
          -  Women not registered with a GP located in Loire-Atlantique will not be included.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cedric RAT, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne-Sophie BANASZUK, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de coordination des d√©pistages des cancers (CRCDC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cedric RAT, Professor</last_name>
    <phone>02.40.41.28.28</phone>
    <email>cedric.rat@univ-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cedric RAT, Professor</last_name>
      <phone>02.40.41.28.28</phone>
      <email>cedric.rat@univ-nantes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 27, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical cancer screening</keyword>
  <keyword>General Practitioner</keyword>
  <keyword>Organized screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

